Blood, Vol. 90 No. 6 (September 15), 1997:
pp. 2513-2513
ERRATUM
In the article by Basser et al entitled "Randomized, Blinded, Placebo-Controlled Phase I Trial of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor With Filgrastim After Dose-Intensive Chemotherapy in Patients With Advanced Cancer," which appeared in the May 1, 1996 issue (Vol 89, No 9, pp 3118-3128), corrections should be noted. In Table 5 the numbers were misaligned and figure legends 1 and 2 contained errors. The corrected table and figure legends are printed below
Fig 1.
Median platelet counts after chemotherapy for patients given PEF-rHuMGDF 0.03 (
, n = 3), 0.1 µg/kg (
, n = 3), 0.3 µg/kg (
, n = 3), 1.0 µg/kg (
, n = 11), 3.0 µg/kg (
, n = 7), or 5.0 µg/kg (
, n = 4), and placebo (
, n = 10). The horizontal bar indicates a platelet count of 100 × 109/L.
Fig 2.
(A) shows platelet recovery for all patients given PEG-rHuMGDF (, n = 25) and those given placebo (, n = 10). (B) shows the Kaplan-Meier plot of the probability of recovery to baseline platelet counts in these groups. The median time to baseline counts was 18 days for PEG-rHuMGDF and 22 days for placebo (P = .014, log rank test).
